ASCO Preview: Immutep, InxMed and Faron Release New Clinical Findings

The American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3 to 7 will introduce hundreds of posters, abstracts and presentations of exciting cancer studies, preclinical and clinical. Here’s a look ahead at just three international presenters.

Immutep to Present Interim Data from Lung Cancer Trial

Australia’s Immutep will present new interim data from Part A of its Phase II TACTI-002 in first-line non-small cell lung cancer (NSCLC). The study is evaluating eftilagimod alpha in combination with Merck’s anti-PD-L1 checkpoint inhibitor Keytruda (pembrolizumab).